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Abstract: Background: The objective benefits of low dose radiotherapy (LDRT) for non-malignant joint
disorders are controversial. This study evaluated changes in pain, quality of life (QoL) and function after
LDRT for epicondylitis, plantar fasciitis, and finger osteoarthritis. Materials and Methods: Patients over
40 years old with epicondylitis, plantar fasciitis, and finger osteoarthritis were had pain following at least
6 months of conservative therapy. Patients received 0.5 Gy LDRT twice weekly for 4 weeks repeated once
after 8 weeks in patients who failed to achieve complete pain relief. Patients assessed their pain according
to the visual analog scale. Handgrip strength was measured with an isometric dynamometer and the fast
self-paced walking test was used in patients with plantar fasciitis. QoL was evaluated according to the
EQ-5D and HAQ-DI questionnaires. Results: Outcomes for 157 patients (204 sites) were documented at
2, 6, and 12 months after last LDRT. Pain reduction at rest (p < 0.001), during activity (p < 0.001) and
increase in handgrip strength (extension p < 0.001, flexion p = 0.002) were highly significant for patients
with lateral epicondylitis. Patients with medial epicondylitis reported pain relief at rest (p = 0.041) and
during activity (p = 0.041) and significant increase in handgrip strength (p = 0.022). Patients with plantar
fasciitis reported pain reduction at rest (p < 0.001), during activity (p < 0.001) and faster walking times
(p < 0.001). A trend toward improved QoL was observed. Patients with finger osteoarthritis reported
significant pain relief during activity (p < 0.001) and a gain in handgrip strength (p = 0.004), with a
trend to both pain relief at rest (p = 0.056) and stronger pinch grip (p = 0.099). Conclusions: LDRT
achieved significant pain relief at rest and during activity and a corresponding objective improvement
in handgrip strength in patients with epicondylitis. Pain relief at rest, during activity and improvement
in walking time were demonstrated in patients with plantar fasciitis. LDRT achieved pain relief during
activity, and handgrip strength was improved in patients with finger osteoarthritis. No significant effect
was seen on quality of life measures for these conditions. The observed benefits were maintained 12
months after LDRT for all 3 indications and we recommend this low cost, safe intervention for patients
over 40 who have failed prior conservative therapy.
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Background: The objective benefits of low dose radiotherapy (LDRT) for non-malignant
joint disorders are controversial. This study evaluated changes in pain, quality of life (QoL)
and function after LDRT for epicondylitis, plantar fasciitis, and finger osteoarthritis.
Materials and Methods: Patients over 40 years old with epicondylitis, plantar fasciitis,
and finger osteoarthritis were had pain following at least 6 months of conservative
therapy. Patients received 0.5Gy LDRT twice weekly for 4 weeks repeated once after 8
weeks in patients who failed to achieve complete pain relief. Patients assessed their pain
according to the visual analog scale. Handgrip strength was measured with an isometric
dynamometer and the fast self-paced walking test was used in patients with plantar
fasciitis. QoL was evaluated according to the EQ-5D and HAQ-DI questionnaires.
Results:Outcomes for 157 patients (204 sites) were documented at 2, 6, and 12months
after last LDRT. Pain reduction at rest (p< 0.001), during activity (p< 0.001) and increase
in handgrip strength (extension p < 0.001, flexion p = 0.002) were highly significant
for patients with lateral epicondylitis. Patients with medial epicondylitis reported pain
relief at rest (p = 0.041) and during activity (p = 0.041) and significant increase in
handgrip strength (p = 0.022). Patients with plantar fasciitis reported pain reduction at
rest (p < 0.001), during activity (p < 0.001) and faster walking times (p < 0.001). A
trend toward improved QoL was observed. Patients with finger osteoarthritis reported
significant pain relief during activity (p < 0.001) and a gain in handgrip strength (p =
0.004), with a trend to both pain relief at rest (p = 0.056) and stronger pinch grip (p
= 0.099).
Conclusions: LDRT achieved significant pain relief at rest and during activity and a
corresponding objective improvement in handgrip strength in patients with epicondylitis.
Rogers et al. Radiotherapy for Pain and Function
Pain relief at rest, during activity and improvement in walking time were demonstrated
in patients with plantar fasciitis. LDRT achieved pain relief during activity, and handgrip
strength was improved in patients with finger osteoarthritis. No significant effect was seen
on quality of life measures for these conditions. The observed benefits were maintained
12 months after LDRT for all 3 indications and we recommend this low cost, safe
intervention for patients over 40 who have failed prior conservative therapy.
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BACKGROUND
Preclinical studies have shown that 0.3-1.0Gy of radiation
inhibits cell adhesion (1, 2) by increased production of TGF-
beta1 (3, 4), reduced E-selectin expression in endothelial cells
(1, 4) and induction of leucocyte apoptosis (5, 6). Radiation
can also inhibit production of nitrous oxide in macrophages,
leading to apoptosis (7) and reduced free radical production (8).
These in vitro mechanisms have been substantiated in in vivo
models (9, 10) and thus it is plausible that radiation-induced
suppression of inflammatory cascades can achieve clinical pain
relief in non-malignant musculoskeletal disorders with an active
inflammatory component.
Arthritis and tendonitis are inflammatory conditions that
arise in response to infectious, chemical or physical injury. They
have different etiologies but common underlying inflammatory
processes. Lateral and medial epicondylitis arise through
repetitive strain injury that disrupts the connective tissue
at the tendon insertion. The prevalence in adults over 40
years old is between 1 and 4% (11), particularly affecting the
dominant arm (12–14). Plantar fasciitis affects 8–10% of the
population with preponderance in females over the age of 40.
Repeated microtrauma due to incorrect foot pronation (15),
often exacerbated by a high body mass index and inappropriate
footwear, can lead to chronic inflammation of the plantar fascia
with pain on walking. Finger osteoarthritis affects 20–40% of
the population aged 60–70 years of age in Europe and the
United States, with a female tomale ratio of 3:1. This degenerative
joint disease is associated with low-grade inflammation that
affects bone, ligaments, cartilage and synovial tissue. It is a
heterogeneous condition with a multifactorial etiology and is one
of the leading causes of disability worldwide (16).
The first line management of these inflammatory conditions
may be pharmacological, typically topical or oral non-steroidal
anti-inflammatory drugs, (NSAIDs) or non-pharmacological
(17–19). The latter include instruction in joint protection
techniques, assistive devices to help patients perform activities
of daily living (ADLs), thermal modalities and splints (20). Low
dose radiotherapy (LDRT) is reported to be an effective treatment
for therapy-resistant non-malignant musculoskeletal disorders
associated with only minimal toxicities and low costs (21).
Abbreviations: PROMs, patient-reported outcome measures; LDRT, low dose
radiotherapy; VAS, visual analog scale; QoL, quality of life; fSPWT, fast self-paced
walking test; HAQ-DI, Health Assessment Questionnaire-disability index; EQ-5D,
EurolQol-5 dimensions; DRK, Deutsches Register Klinische Studien.
Numerous retrospective series describe response rates of 63–
89% following LDRT for non-malignant joint disorders (22). 7–
70% of patients with epicondylitis benefited from a reduction
in pain levels and complete pain relief was reported in 13–
81% of patients following total radiation doses between 3.0 and
6.0 Gray (Gy), at 0.5–1.0Gy per fraction and 2 fractions a
week across several studies according to the von Pannewitz 4
point scale (23–25). A review of 2000 patients with epicondylitis
treated with LDRT describes a response rate in excess of
70% in most publications. (23, 26–28). In the case of plantar
fasciitis, 7–70% of patients reported some reduction in pain
levels and complete pain relief was reported by 13–81% of
patients (25). Randomized trials in patients with plantar fasciitis
reported a superior effect with 6Gy than 0.6Gy suggesting a is
consistent with a relevanffect of LDRT (29, 30), but no effect
of fraction size could be seen (0.5Gy vs. 1.0Gy) (31). Over
75% of patients with osteoarthritis of the fingers and hand
report pain relief, sustained for more than 5 years in 50%,
even in those with a 10 year history of the condition (32) and
more than 80% of patients benefit from a second course of
LDRT (32).
In 2014 in Germany, 16,989 patients with non-malignant
musculoskeletal conditions were irradiated to improve quality
of life through pain relief and gain in function (33). Patients
with non-malignant conditions account for 20% of the
radiotherapy patient population in our center and low dose
radiotherapy (LDRT) is frequently employed with good patient-
reported outcomes. We therefore performed an evaluation
of subjective changes in pain and quality of life and of
objective changes in musculoskeletal function following low
dose radiotherapy in patients with refractory pain who
had failed standard pharmacological and non-pharmacological
management options.
The aim of this study was to assess objective changes
in musculoskeletal function in addition to patient-
reported outcome measures (PROMs) in patients with
lateral and medial epicondylitis, plantar fasciitis, and
finger osteoarthritis following LDRT as applied in
our practice.
METHODS
The trial was approved by the institutional review board
(Ethikkommission Aargau-Solothurn, Aarau, Switzerland) and
registered with the German Registry for Clinical Studies
(No. DRK 500006288). Informed consent was obtained for
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FIGURE 1 | Isometric hydraulic dynanometer (JAMAR®, USA) for handgrip
strength.
inclusion of patients in the study. This prospective, uncontrolled
interventional trial was performed in a single center setting and
was conducted according to Good Clinical Practice and the
declaration of Helsinki. The trial closed 12 months after the last
patient was treated.
Consecutive patients with persistent pain from lateral and
medial epicondylitis, plantar fasciitis and finger osteoarthritis
who were referred for LDRT for were recruited between 01/2013
and 10/2015. Inclusion criteria were (1) age >40, (2) Karnofsky
performance status >70, (3) non-pregnant or non-lactating if
female, (4) effective contraception for 12 months if relevant and
(5) prior treatment with conservative measures (physiotherapy,
orthopedic splints or insoles and NSAIDs) for at least 6
months. Exclusion criteria were previous radiotherapy to the
site, radiosensitivity disorders or an inability to comply with the
study protocol.
Informed consent was obtained by the radiation oncologist
and patients completed two questionnaires validated in German:
EuroQol-5 dimension (EQ-5D) for quality of life (34) and the
Health Assessment Questionnaire (HAQ) (35, 36) for level of
independence from which the Standard Disability Index was
derived (DI). Patients scored their pain level between 0 and
10 according to the visual analog scale (VAS) at rest and
during activity. A board-certified physiotherapist documented
musculoskeletal function according to the anatomical site.
Handgrip strength was tested in a sitting position using an
isometric hydraulic dynamometer (JAMAR R©, USA) (Figure 1)
in elbow flexion for medial epicondylitis and in both flexion and
extension for lateral epicondylitis.
Handgrip strength was tested in all patients with finger
osteoarthritis, but pinch grip strength (37) only in those receiving
FIGURE 2 | Isometric hydraulic dynanometer (JAMAR®, USA) for pinch grip
strength.
thumb carpo-metacarpal irradiation using the designated
JAMAR R© dynamometer (Figure 2).
Impairment of function due to plantar fasciitis was measured
by the fast self-paced walking test (fSPWT), which counts the
time taken to walk 20 meters (38). This simple test requires
minimal instruction and has been used in randomized trials
to measure the effect of therapeutic intervention due to robust
reliability (37) and sensitivity to change in performance across
diagnostic groups (39, 40).
Patients were irradiated with 8 x 0.5Gy twice a week on
non-consecutive days over 4 weeks to a total dose of 4.0Gy
with 200 kV orthovoltage direct fields (Therapax, Pantak, CT,
USA). Non-target joints and, in the case of finger irradiation nail
beds, were shielded with lead (Supplementary Figure 1). The
dose prescription was the departmental standard at the time the
study was initiated following reports of efficacy with a total dose
between 3.0 and 6.0Gy across the three indications (41).
LDRT was repeated up to a dose of 8.0Gy in patients who did
not achieve a complete pain response with the first course (42).
Follow-up tests of functionality (handgrip, pinch grip strength
and fast self-paced walking test) were performed at 2, 6, and 12
months after irradiation. VAS pain scores, and EQ-5D and HAQ-
DI questionnaires were completed by the patients at these visits.
Statistical Analysis
The study endpoints were VAS pain scores, handgrip and
pinch grip strength (kg), walking time (seconds), EQ-5D score
(calculated on the regression coefficients of the lean model for
the German reference population) andHAQ-DI score. Outcomes
were evaluated per site and patients with lateral epicondylitis,
medial epicondylitis, finger osteoarthritis and plantar fasciitis
were analyzed separately.
Descriptive summary statistics (mean, standard deviation,
median, interquartile range, minimum and maximum, number
of available data) are presented for each time point for
each analysis set (Supplementary Tables 1–4). The differences
compared with baseline at 2, 6, and 12 months after LDRT
appeared so large that post hoc testing of median changes was
performed (paired Wilcoxon signed rank test). The two-sided
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No. of patients 35 9 59 54
Age 50.0 (7.8) 56.8 (6.5) 62.4 (9.0) 52.4 (7.7)
Gender = female 20 (57.1) 7 (77.8) 52 (88.1) 43 (79.6)
Total.sessions = 2 22 (62.9) 7 (77.8) 46 (78.0) 34 (63.0)
Irradiated side
Bilateral 4 (11.4) 1 (11.1) 40 (67.8) 2 (3.7)
Left 11 (31.4) 4 (44.4) 10 (16.9) 22 (40.7)
Right 20 (57.1) 4 (44.4) 9 (15.3) 30 (55.6)
Age: mean (s.d.), other variables: frequency (%).
p-values were adjusted for multiple comparisons (Bonferroni-
Holm method). An adjusted p-value of less than 0.05 was
considered statistically significant. Spearman’s rank correlation
coefficient (rho) was calculated to assess the relationship between
changes in pain scores and functional test outcomes for lateral
epicondylitis and plantar fasciitis. A smoothing function was
fitted to the EQ-5D and the HAQ-DI scores using locally
weighted smoothing (LOESS) to allow an estimation of the
overall time trend. All statistical analyses were conducted using
the statistical software package R (43).
RESULTS
One hundred and fifty-seven patients [lateral epicondylitis
(35), medial epicondylitis (9), finger osteoarthritis (59) and
plantar fasciitis (54)] with 204 sites were treated: lateral
epicondylitis (39), medial epicondylitis (10), finger osteoarthritis
(99) and plantar fasciitis (56). The low number of patients with
medial epicondylitis reflects its incidence. All patients reported
limitations in activities of daily living (ADL) due to pain at rest or
during activity. Patient characteristics are summarized inTable 1.
Complete pain response (VAS 0) was achieved in 55/204
(27%) of sites after the first course of low dose radiotherapy
and therefore the second course of LDRT was not given
in these patients. The planned second course of LDRT was
delivered in 149/204 (73%) sites after 2–12 months (25/39
lateral epicondylitis, 8/10 medial epicondylitis, 81/99 finger
osteoarthritis, 35/56 plantar fasciitis). Eighty percent (165/204)
of treated sites could be assessed at 12 months (30/38
lateral epicondylitis, 6/10 medial epicondylitis, 82/100 finger
osteoarthritis for handgrip and 53/65 for pinch grip, 30/38
plantar fasciitis). All patients who attended for follow-up at 2, 6,
and 12 months returned the quality of life questionnaires.
The data points for each set at 2, 6, and 12 months after last
LDRT (12 months after the first course if one course was given
or the second course in the event of 2 courses of irradiation) are
shown in violin plots (Supplementary Figures 2–5). The median
changes in pain and outcome scores 2, 6, and 12 months after last
LDRT compared with baseline are summarized in Table 2.
TABLE 2 | Median changes and p-values from the Wilcoxon signed rank test for
different outcomes of each analysis set assessed at 2, 6, and 12 months after the
last LDRT session compared to the baseline values before the start of the first
LDRT session.








Pain at rest 2 −2 [−5, 0] <0.001
Pain at rest 6 −1 [−4.25, 0] 0.01
Pain at rest 12 −2.5 [−5, 0] <0.001
Pain during activity 2 −4 [−6, −2] <0.001
Pain during activity 6 −5 [−7, −2] <0.001
Pain during activity 12 −6 [−7, −4] <0.001
Handgrip in flexion 2 4 [−2, 9] 0.016
Handgrip in flexion 6 4.5 [0, 15] 0.002
Handgrip in flexion 12 5.25 [0, 11.75] 0.002
Handgrip in extension 2 9.5 [−0.075, 20.75] <0.001
Handgrip in extension 6 16 [5, 23] <0.001
Handgrip in extension 12 16 [5.5, 23.75] <0.001
Medial
epicondylitis
Pain at rest 2 −2.5 [−3.375, −0.75] 0.04
Pain at rest 6 −3 [−5.75, −2.5] 0.04
Pain at rest 12 −3 [−4.5, −2.25] 0.04
Pain during activity 2 −2.5 [−4.25, −0.75] 0.04
Pain during activity 6 −4 [−6.25, −3] 0.045
Pain during activity 12 −4 [−6.25, −3.25] 0.04
Handgrip in flexion 2 −4 [−5, 3] 0.722
Handgrip in flexion 6 6 [4, 7.25] 0.04
Handgrip in flexion 12 6.5 [4.25, 8.5] 0.022
Finger
osteoarthritis
Pain at rest 2 −0.75 [−3, 0] <0.001
Pain at rest 6 −1 [−4, 0] <0.001
Pain at rest 12 0 [−3.5, 0.25] 0.03
Pain during activity 2 −1.5 [−4, 0] <0.001
Pain during activity 6 −2.25 [−5, 0] <0.001
Pain during activity 12 −3 [−5, 0.5] <0.001
Handgrip in flexion 2 2 [−2, 5.5] 0.026
Handgrip in flexion 6 3 [−3, 7] 0.016
Handgrip in flexion 12 2.5 [−1, 6] 0.004
Pinch grip 2 0.5 [−0.5, 1.5] 0.054
Pinch grip 6 0.5 [−0.125, 2] 0.001
Pinch grip 12 0.5 [−0.5, 1.625] 0.101
Plantar
fasciitis
Pain at rest 2 −3 [−5, 0] <0.001
Pain at rest 6 −4 [−6, 0] <0.001
Pain at rest 12 −4 [−6, 0] <0.001
Pain during activity 2 −4 [−6.25, −2.75] <0.001
Pain during activity 6 −6.5 [−8, −3.75] <0.001
Pain during activity 12 −6 [−8, −4] <0.001
Walking test 2 −2 [−6, −0.25] <0.001
Walking test 6 −4 [−6, −1.5] <0.001
Walking test 12 −5 [−8, −2.5] <0.001
P-values were adjusted for multiple comparisons using the Bonferroni-Holm method. Pain
was scored with the visual analog scale (VAS). Median handgrip and pinch grip strength
are reported in kilograms and walking time is in seconds.
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TABLE 3 | Correlations between changes in pain (VAS) and functional outcomes of specific interest after last LDRT session.
Data set Change between Correlation Spearman’s rho [95% CI] p–value
Lateral epicondylitis 0–2 months Handgrip flexion vs. pain at rest −0.5 [−0.71, −0.21] 0.009
0–2 months Handgrip flexion vs. pain during activity −0.64 [−0.8, −0.4] <0.001
0–6 months Handgrip flexion vs. pain at rest −0.3 [−0.59, 0.05] 0.138
0–6 months Handgrip flexion vs. pain during activity −0.03 [−0.38, 0.32] 0.842
0–12 months Handgrip flexion vs. pain at rest −0.54 [−0.76, −0.22] 0.01
0–12 months Handgrip flexion vs. pain during activity −0.39 [−0.66, −0.02] 0.086
0–2 months Handgrip extension vs. pain at rest −0.46 [−0.68, −0.16] 0.011
0–2 months Handgrip extension vs. pain during activity −0.7 [−0.84, −0.49] <0.001
0–6 months Handgrip extension vs. pain at rest −0.38 [−0.64, −0.03] 0.054
0–6 months Handgrip extension vs. pain during activity −0.33 [−0.61, 0.02] 0.333
0–12 months Handgrip extension vs. pain at rest −0.47 [−0.71, −0.13] 0.02
0–12 months Handgrip extension vs. pain during activity −0.36 [−0.64, 0.02] 0.092
Medial epicondylitis 0–2 months Handgrip flexion vs. pain at rest −0.35 [−0.85, 0.47] 0.649
0–2 months Handgrip flexion vs. pain during activity −0.35 [−0.85, 0.47] 0.239
0–6 months Handgrip flexion vs. pain at rest 0.15 [−0.68, 0.81] 0.607
0–6 months Handgrip flexion vs. pain during activity −0.65 [−0.94, 0.21] 0.037
0–12 months Handgrip flexion vs. pain at rest −0.32 [−0.9, 0.66] 0.392
0–12 months Handgrip flexion vs. pain during activity −0.55 [−0.94, 0.47] 0.58
Finger osteoarthritis 0–2 months Handgrip vs. pain at rest −0.28 [−0.46, −0.09] 0.031
0–2 months Handgrip vs. pain during activity −0.36 [−0.52, −0.18] 0.011
0–6 months Handgrip vs. pain at rest −0.24 [−0.43, −0.03] 0.049
0–6 months Handgrip vs. pain during activity −0.42 [−0.58, −0.22] 0.001
0–12 months Handgrip vs. pain at rest −0.35 [−0.53, −0.14] 0.002
0–12 months Handgrip vs. pain during activity −0.48 [−0.63, −0.28] <0.001
0–2 months Pinch grip vs. pain at rest −0.3 [−0.51, −0.05] 0.032
0–2 months Pinch grip vs. pain during activity −0.36 [−0.56, −0.12] 0.01
0–6 months Pinch grip vs. pain at rest −0.32 [−0.54, −0.05] 0.031
0–6 months Pinch grip vs. pain during activity −0.31 [−0.54, −0.04] 0.036
0–12 months Pinch grip vs. pain at rest −0.31 [−0.54, −0.03] 0.054
0–12 months Pinch grip vs. pain during activity −0.29 [−0.52, −0.01] 0.1
Plantar fasciitis 0–2 months Walking test vs. pain at rest 0.36 [0.09, 0.58] 0.054
0–2 months Walking test vs. pain during activity 0.49 [0.25, 0.68] 0.012
0–6 months Walking test vs. pain at rest 0.4 [0.12, 0.63] 0.011
0–6 months Walking test vs. pain during activity 0.41 [0.13, 0.63] 0.009
0–12 months Walking test vs. pain at rest 0.31 [−0.01, 0.58] 0.239
0–12 months Walking test vs. pain during activity 0.43 [0.13, 0.66] 0.049
P-values were adjusted for multiple comparisons using the Bonferroni-Holm method. Rho=Spearman’s rank correlation coefficient.
Lateral Epicondylitis
Patients with lateral epicondylitis had higher baseline median
pain scores during activity than at rest (6.0 vs. 3.0). A median
pain score of 0 at rest was reached 2 months after LDRT (p =
0.006), and during activity after 12 months (p = 0.002). This
pattern was observed after the first and second course of LDRT.
Median change in pain score 12 months after last LDRTwas−2.5
(p < 0.001) at rest, and −6.0 (p < 0.001) during activity. At
rest, 23/31 (74%) treated sites responded completely and 21/27
(78%) patients were pain free at 12months. During activity, 13/30
(43%) treated sites and 11/28 (39%) patients were pain free at 12
months. Median change in handgrip strength 12 months after
last LDRT was 5.2 kg (p = 0.002) in elbow flexion and 16.0 kg
(p < 0.001) in elbow extension (Table 2). There were inverse
correlations between handgrip strength in elbow extension and
pain at rest (rho = −0.6, p < 0.001) and pain during activity
(rho = −0.5, p < 0.001) (Table 3). No trend was visible for the
EQ-5D total score for patients with lateral epicondylitis whilst
for the HAQ-DI, there may have been a slight decrease over time
(Supplementary Figure 6).
Medial Epicondylitis
12 months after last LDRT, median pain scores at rest and during
activity were both 0 (p = 0.331 and p = 0.249, respectively). At
rest, 5/6 treated sites (83%) were pain free at 12 months. Median
changes in pain 12months after last LDRTwere:−3.0 (p= 0.041)
at rest and −4.0 (p = 0.041) during activity (Table 2). Median
change in handgrip strength after 12 months showed a significant
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increase (6.5 kg, p = 0.022). Quality of life seemed to increase
after radiotherapy according to the EQ-5D but not the HAQ-DI
score (Supplementary Figure 7).
Finger Osteoarthritis
Pain at rest due to finger osteoarthritis was low prior to therapy
(median: 2.0) and did not decrease significantly after last LDRT
(median change= 0, p= 0.056). At rest, 40/83 (48%) treated sites
(27/48: 56% patients) were pain free at 12 months. In contrast,
pain during activity was high at baseline (median: 5.0) and
decreased significantly after last LDRT (median change = −3.0,
p < 0.001). During activity, 11/83 (13%) treated sites (9/48: 19%
patients) had VAS scores of 0 at the same time point. A significant
improvement was seen for handgrip strength (median change =
2.5 kg, p = 0.004) but not pinch grip (median change 0.5 kg, p =
0.099) at 12 months. No clear trend was visible in either EQ-5D
total score or HAQ-DI (Supplementary Figure 8).
Plantar Fasciitis
Both pain at rest and during activity decreased rapidly after
radiotherapy for plantar fasciitis. Pain at rest decreased from a
median VAS of 1.0–0.0 2 months after last LDRT (median change
= 0.0, p = 0.003) and was sustained for 12 months. Median
change in pain at rest at 12 months was −4.0 (p < 0.001). 38
of 41 (93%) sites evaluated at 12 months (38/41 patients, 93%)
were pain free. In comparison, pain scores during activity were
higher before LDRT (VAS: 6.0) but decreased to a VAS of 0
after 6 months (median change = −4.0, p < 0.001). 28 of 41
sites evaluated at 12 months (28/41 patients, 68%) were pain free
during activity. Median change in pain during activity 12 months
after last LDRT was−6.0 (p< 0.001). Performance in the fSPWT
also improved significantly. At 12months after LDRT, themedian
walking time was 5.0 s quicker (p < 0.001) compared with before
first LDRT. At 12 months, the correlation between walking time
and pain during activity (rho= 0.5, p < 0.001) was stronger than
with pain at rest (rho = 0.2, p = 0.008). There seemed to be a
slight increase in EQ-5D total score) but not for the HAQ-DI
(Supplementary Figure 9).
DISCUSSION
This study demonstrates effective pain relief and objective gain
in musculoskeletal function with LDRT across multiple non-
malignant joint disorders.
Other than a dose finding study (26), this is the first
prospective account of the pain response to LDRT in patients
with lateral epicondylitis and medial epicondylitis and the first
to document a significant parallel improvement in handgrip
strength. Together with a retrospective review comprising 2,141
patients with epicondylitis (23), this cohort confirms the ability
of LDRT to achieve 63–83% complete pain control in this
condition. Due to the low number of patients with medial
epicondylitis (n = 9), the data cannot be considered statistically
meaningful, however the median 6.5 kg increase in handgrip
strength 12 months after LDRT and pain reduction of 3–4 VAS
points strongly suggest efficacy in both medial epicondylitis and
lateral epicondylitis.
Patients with finger osteoarthritis and pain during activity
reported pain relief following LDRT, however, the reduction in
pain relief at rest did not quite reach statistical significance,
although there was a trend to improvement 12 months after
LDRT as compared with prior to first LDRT. The low baseline
VAS scores at rest-16/59 patients (27%) had median VAS 0 at
rest but pain during activity-may have been a contributory factor.
This pattern of pain during activity but not at rest is characteristic
of osteoarthritis (44).
This study confirms the effectiveness of LDRT for the pain
relief of plantar fasciitis, consistent with complete response rates
of up to 81% reported in a review of 11,909 patients from 22
studies (22). Predictive factors for response to LDRT for plantar
fasciitis include a megavoltage technique and one treatment
series (45). We used orthovoltage radiotherapy but obtained
response rates comparable to those achieved with megavoltage
irradiation, therefore the 200 kV beam profile was adequate. Two
courses of LDRT were given in 34/54 (63%) patients with plantar
fasciitis who were not pain free 2–12 months after the first course
of radiotherapy, but sustained pain control at 12 months was also
feasible with one course of total 4.0Gy in 20 (37%) patients.
We showed a corresponding improvement in function
after LDRT for plantar fasciitis. Guidelines from the American
Physical Therapy Society recommend: “. . . easily reproducible
activity limitation and participation restriction measures
associated with their patient’s heel pain/plantar fasciitis to
assess the changes in the patient’s level of function. . . ” (46).
The fSPWT is a reliable performance indicator in patients with
osteoarthritis of the hip and knee (47, 48), although re-testing
within 21 days has shown some variability (49). We were unable
to control for normal variability in our cohort, however median
walking times were 5 s faster (23 times the variability reported
above) which indicates a genuine effect. The positive correlation
between reduction in pain levels during activity and walking
times suggests this test could become a validated functional test
for plantar fasciitis.
The improved pain and function test scores did not translate
into significant improvements in quality of life or improvement
in functional independence for any subgroup as evaluated
by EQ-5D and HAQ-DI, respectively. Trends to increased
function and decreased invalidity could be seen in 50% of the
analysis sets (EQ-5D: medial and lateral epicondylitis, HAQ-DI:
medial epicondylitis and plantar fasciitis), however the medial
epicondylitis group contained only a small number of patients.
It is possible that these questionnaires did not clearly show a
corresponding benefit in quality of life as the questions address
practical issues which are likely to be limited by chronic joint
deformity (50) on which LDRT has no impact. The EQ-5D is a
validated but generic questionnaire and it has been suggested that
the combination of both a generic and a disease-specific quality
of life measure (51) can better detect treatment effects (52). A
recent evaluation of the HAQ-DI in generalized osteoarthritis
found good construct validity, internal consistency and reliability
but that its content validity and responsiveness were limited and
adaptations were recommended (53). Furthermore, the EQ-5D
has been mainly utilized in hip and knee osteoarthritis rather
than the conditions studied in this trial, which may explain
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why little benefit on quality of life was documented despite a
substantial effect on pain.
Themain limitation of this study is that concomitant analgesia
could not be interpreted as non-malignant musculoskeletal
conditions such as osteoarthritis usually affect more than
one anatomical site and dosage may be altered due to pain
at a non-irradiated site. Although a transient pain flare
may require additional medication, the subsequent sustained
analgesic benefits of radiotherapy can reduce the need for
long-term analgesia and the associated potential toxicities (54).
Study patients had failed to respond to at least 6 months of
conservative therapies including physiotherapy, non-steroidal
anti-inflammatory analgesia and orthopedic splints or insoles
and it is very unlikely that the reduction in pain and gain in
function were due to spontaneous improvement.
Randomized data for LDRT in non-malignant conditions
are scarce (30, 31, 55, 56) and without adequately powered
randomized controlled trials (RCT), the benefit of LDRT cannot
be concluded. A previous clinical trial with 62 patients with
plantar fasciitis showed superior efficacy of 6.0Gy over 0.6Gy
and was closed early on ethical grounds, strongly supporting a
real benefit from radiotherapy (29). The statistical correlations
between pain relief and functional outcomes across the disease
entities in the current study are consistent with a relevant effect of
LDRT. Although the study was uncontrolled, the lack of blinding
is not expected to have had any significant impact on the objective
functional tests (57).
Two recent sham-controlled RCTs failed to demonstrate any
beneficial effect of 1.0Gy weekly for 6 weeks in patients with
osteoarthritis of the hand (56) and knee (55). Sham irradiation
raises ethical questions however because the radiotherapy team
must engage in active deception as only the patient is unaware
whether radiotherapy has been delivered or not. Of note, neither
of the above trials included objective functional tests as utilized
in this study. The strength of handgrip and pinch grip have
been found to be reliable and sensitive to change in patients
with osteoarthritis of the hand (58). The association between
grip strength and questionnaires assessing physical function
is reportedly limited and the latest recommendations of the
Osteoarthritis Research Society (OARSI) are to include grip
strength as an outcome to improve the quality of clinical trials
(59), as performed in this study. We found the changes in
musculoskeletal function could be meaningfully evaluated using
the handgrip strength dynamometer and the fast self-paced
walking test may be usefully incorporated into future clinical
trials non-malignant disorders of the lower limb.
The primary endpoint of the above sham-controlled RCT
was “proportion of responders” (i.e., pain relief and subjective
assessment of function) and this was not statistically different in
the experimental (29% hand, 44% knee) and the sham (36% hand,
43% knee) groups. Patients received only one course of LDRT
and the primary endpoint was assessed after only 3 months. In
our study, two courses of LDRT were standard and received
by 73% of patients who had an incomplete pain response after
the first course. It has been observed that patients with plantar
fasciitis, epicondylitis, and hand osteoarthritis benefit from a
second course of LDRT after 8 weeks (60). A large retrospective
cohort of patients with arthritis and enthesopathies reported that
response to therapy developed many months after completion
of therapy: a median VAS score of 7.0 prior to LDRT, 5.0
immediately after, 4.0 after 12 weeks and 1.0 after 38 months
(61). In contrast, longer follow-up of the patients with hand
osteoarthritis in the sham-controlled randomized trial of LDRT
with a single course of 6× 1.0Gy weekly showed no difference in
benefit between the experimental and sham groups at 6 and at 12
months (62). A further randomized trial is needed to ascertain
whether the apparent benefit in the previous studies is due to
regression to the mean or placebo effect or indeed LDRT. The
data from the Arthorad randomized trial (6 × 0.5Gy vs. 6 ×
0.05Gy) from the DEGRO group are awaited at the end of 2020.
We therefore endorse the comments by Ott et al. (63) that these
trials are not yet practice changing as patient numbers were low,
the prescription of 1.0Gy weekly for 6 weeks was not standard,
and that the 3 month follow-up is short. We also report lesser
clinical benefit of LDRT in patients with finger osteoarthritis,
which we attribute to underlying complex joint deformities
that are not expected to respond to LDRT. The benefits of
LDRT for patients with pain at rest from finger osteoarthritis
and could not be demonstrated in our study, putatively due
to low baseline pain levels. Osteoarthritis data should not be
extrapolated to epicondylitis and plantar fasciitis where LDRT is
highly successful. Our study protocol used the 2013 departmental
standard of 8× 0.5Gy, however our current practice is 6× 0.5Gy
(31) repeated after a minimum interval of 8 weeks in the absence
of a complete pain response.
Many countries do not offer radiotherapy for benign
conditions, mostly due to concerns about the potential for
radiation-induced malignancy. As the population in many
countries is aging and such disorders result in significant
impairment in quality of life and costs, there is now a wider
international interest in LDRT (64). As a precaution, we do
not offer LDRT to patients under 40 years old or to those
whose family planning is not yet complete, although dose to
the reproductive organs is low (32). No patients in our cohort
reported any toxicity. Acute skin toxicities greater than grade 1
are rare (23, 29) and, importantly, no induced tumors have ever
been reported (30, 65). As the median age of LDRT patients is
65 years, any potential risks should be offset by the potential
benefits (66).
CONCLUSIONS
Patients with refractory pain from lateral epicondylitis, plantar
fasciitis and finger osteoarthritis with pain during activity
reported significant pain relief and demonstrated improved
musculoskeletal function sustained after 12 months. The
improved pain and functional test scores were not associated with
improved quality of life as evaluated by the EQ-5D and HAQ-DI
questionnaires. LDRT with 6 x 0.5Gy, repeated after a minimum
of 8 weeks in the absence of a complete pain response, may be
offered to patients over 40 years old as a safe, non-toxic treatment
modality which may achieve sustained pain relief and improved
functional outcomes 12 months after the last treatment.
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